Recently, some FAK inhibitors have been investigated for their efficacy in mitigating NSCLC response to radiation, chemotherapies, and targeted therapies such as RTK inhibitors or PDL/PDL1-based immunotherapies (Jiang et al., 2016). The gene discussed is PTK2; the disease is non-small cell lung carcinoma.